1:31 PM
Nov 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Diffusion to start Phase III GBM trial of TSC

By year end, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) will begin a Phase III trial to compare trans sodium crocetinate (TSC) plus standard of care (SOC), including chemotherapy and radiation, vs. SOC alone to treat newly diagnosed,...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >